Related Experiment Video

Updated: Jun 17, 2026

Methods for Evaluating the Role of c-Fos and Dusp1 in Oncogene Dependence
10:09

Methods for Evaluating the Role of c-Fos and Dusp1 in Oncogene Dependence

Published on: January 7, 2019

Functional interplay between E2F1 and chemotherapeutic drugs defines immediate E2F1 target genes crucial for cancer

David Engelmann1, Susanne Knoll, Daniel Ewerth

  • 1Department of Vectorology and Experimental Gene Therapy, Biomedical Research Center, University of Rostock, Germany.

Cellular and Molecular Life Sciences : CMLS
|December 17, 2009
PubMed

Insights

This study reveals how E2F1 and chemotherapy cooperate to enhance cancer cell death. Researchers identified new apoptosis genes, like TIEG1/KLF10, crucial for making cancer cells more sensitive to drugs.

Area of Science:

  • Molecular Biology
  • Cancer Research
  • Genetics

Background:

  • The E2F1 transcription factor promotes apoptosis in p53-deficient tumors.
  • Understanding E2F1's interaction with chemotherapy is key for developing effective cancer treatments.

Purpose of the Study:

  • To elucidate the cooperative mechanism between E2F1 and chemotherapy.
  • To identify cooperation response genes (CRGs) regulated by E2F1 and drug treatment.
  • To explore E2F1-driven gene expression in response to anticancer drugs.

Main Methods:

  • Whole-genome microarrays were used on chemoresistant tumor cell lines.
  • CRGs were identified based on synergistic expression upon E2F1 activation and drug treatment.
  • Cluster analysis was performed to compare gene expression patterns.

Main Results:

  • Chemotherapeutics were found to enhance E2F1-dependent gene expression transcriptionally.
  • Novel apoptosis genes, including the tumor suppressor TIEG1/KLF10, were identified as direct E2F1 targets.
  • TIEG1/KLF10 was shown to be transcriptionally activated by E2F1 and essential for E2F1-mediated chemosensitization.

Conclusions:

  • E2F1 plays a critical role in chemosensitizing cancer cells through the regulation of specific genes.
  • The findings provide insights into E2F1-regulated gene networks during cytotoxic treatment.
  • This research facilitates the design of more rational and targeted cancer therapeutics.

More Related Videos

Studying Cell Cycle-regulated Gene Expression by Two Complementary Cell Synchronization Protocols12:02

Studying Cell Cycle-regulated Gene Expression by Two Complementary Cell Synchronization Protocols

Published on: June 6, 2017

Mapping the Structure-Function Relationships of Disordered Oncogenic Transcription Factors Using Transcriptomic Analysis09:58

Mapping the Structure-Function Relationships of Disordered Oncogenic Transcription Factors Using Transcriptomic Analysis

Published on: June 27, 2020

Related Concept Videos

Mitogens and the Cell Cycle02:38

Mitogens and the Cell Cycle

Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase01:11

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase

Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...
Treatment Resistant Cancers02:56

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...